Efficacy of Standardised Treatments Combined with Ubenimex in Patients with Malignant Tumors
Efficacy of Standardised Treatments Combined with Ubenimex in Patients with Malignant Tumors
复制标题
规范化治疗联合乌苯美克斯治疗恶性肿瘤的疗效
DOI：
10.29271/jcpsp.2021.02.206
复制
发表时间：
2021-02-01
影响因子：
1
通讯作者：
Su, Tong
中科院分区：
文献类型：
--
作者：
Hu, Xin;Xiong, Haofeng;Su, Tong
Ubenimex在白血病和非小细胞肺癌治疗中被广泛用作免疫调节剂，以改善抗肿瘤治疗效果。但是，没有任何多中心随机对照试验来研究其对癌症患者预后的影响。作者旨在进行荟萃分析以最初研究这些问题。搜索了PubMed，Cochrane库和Embase。荟萃分析中纳入了Ubenimex对恶性肿瘤患者存活率的影响的随机对照试验。两组之间的存活率比（OR）和95％置信区间（95％CI）用于评估Ubenimex的疗效。固定效应模型用于荟萃分析。包括五项研究的总共1,372例（Ubenimex组为684例，对照组688例）。在Ubenimex组和对照组之间，1年或1.40（95％CI = 1.06至1.85），2年或1.43（95％CI = 1.08至1.89），3年或1.39（95％CI = 1.07至1.81）。与Ubenimex结合使用的标准化治疗可能会提高恶性肿瘤患者的存活率。
Ubenimex is widely used as an immunomodulator in the treatment of leukemia and non-small cell lung cancer to improve the anti-tumor treatment effect. However, there has not been any multicenter randomised controlled trials to study its impact on the prognosis of cancer patients. The authors aimed to conduct a meta-analysis to initially study these issues. Pubmed, Cochrane Library and EMbase were searched. Randomised controlled trials of the effects of ubenimex on the survival rate of malignant tumor patients were included in the meta-analysis. Survival rate ratio (OR) and 95% confidence interval (95% CI) between two groups were used to evaluate the efficacy of ubenimex. Fixed effects models were used for meta-analysis. A total of 1,372 cases (684 in the ubenimex group and 688 in the control group) of five studies were included. Between the ubenimex group and the control group, the 1-year OR was 1.40 (95% CI = 1.06 to 1.85), the 2-year OR was 1.43 (95% CI = 1.08 to 1.89) and the 3-year OR was 1.39 (95% CI = 1.07 to 1.81). Standardised treatments combined with ubenimex may improve the survival rate of patients with malignant tumors.